Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis

Clinical Neuropharmacology

Volumn 33, Issue 6, 2010, Pages 312-316

  Fragoso, Yara Dadalti ^a   Frota, Elizabeth Regina Comini ^b   Lopes, Juarez Silva ^c   Noal, Janaina Silveira ^c   Giacomo, Maria Cristina ^c   Gomes, Sidney ^d   Gonçalves, Marcus Vinicius Magno ^e   Da Gama, Paulo Diniz ^f   Finkelsztejn, Alessandro ^a  

^a UNIVERSIDADE METROPOLITANA DE SANTOS   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Santa Maria ^*

^d Pontificia Universidade Catolica   (Mexico)

^e PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^f HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

depression; interferon beta; multiple sclerosis; suicide

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; FLUOXETINE; GLATIRAMER; HALOPERIDOL; INTERFERON BETA SERINE; OLANZAPINE; PAROXETINE; RISPERIDONE; SERTRALINE;

ADULT; AGGRESSION; CLINICAL ARTICLE; DEPRESSION; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MANIA; MULTIPLE SCLEROSIS; PHOBIA; PRIORITY JOURNAL; PSYCHOSIS; REMISSION; REVIEW; SIDE EFFECT; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT DURATION;

ADULT; BRAZIL; DEPRESSIVE DISORDER; DRUG MONITORING; FEMALE; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; MOOD DISORDERS; MULTIPLE SCLEROSIS; PREVALENCE; SUICIDAL IDEATION; SUICIDE, ATTEMPTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649390621     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181f8d513     Document Type: Review

References (26)

1. Clerico M, Contessa G, Durelli L. Interferon beta 1a for the treatment of multiple sclerosis. Expert Opin Biol Ther 2007;7:535-542.
2. Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst 2001;4:CD002002.
3. Porcel J, Ŕio J, Sánchez-Betancourt A, et al. Long-term emotional state of multiple sclerosis patients treated with interferon beta. Mult Scler 2006;12:802-807.
4. Lebrun C, Cohen M. Depression in multiple sclerosis. Rev Neurol Paris 2009;165(suppl 4):S156-S162.
5. Goeb JL, Cailleau A, Laine P, et al. Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol 2003;26:5-7.
6. Lana-Peixoto MA, Teixeira AL Jr, Haase VG. Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis. Arq Neuropsiquiatr 2002;60:721-724.
7. Mohr DC, Likosky W, Dwyer P, et al. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis. Arch Neurol 1999;56:1263-1265.
8. Ziemssen T. Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 2009;277(suppl 1):S37-S41.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
10. Myint AM, Scwarz MJ, Steinbusch HW, et al. Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis 2009;24:55-68.
11. Raison CL, Demetrashvilli M, Capuron L, et al. Neuropsychiatric adverse effects of interferon alpha: recognition and management. CNS Drugs 2005;19:105-123.
12. Raison CL, Dantzer R, Kelley KW, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010;15:393-403.
13. Naranjo CA, Busto U, Abel JG, et al. Empirical delineation of the probability spectrum of adverse drug reactions. Clin Pharmacol Ther 1981;29:267-268. (Pubitemid 11140804)
14. Naranjo CA, Busto U, Sellers EM, et al. A reliable method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245. (Pubitemid 12149145)
15. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50(1): 121-127.
16. LoFermo S, Barone R, Patti F, et al. Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study. Mult Scler 2010;16:742-748.
17. Fazzito MM, Jordy SS, Tilbery CP. Psychiatric disorders in multiple sclerosis patients. Arq Neuropsiquiatr 2009;67:664-667.
18. Carroll WM. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit. Mult Scler 2009;15:951-958.
19. Boyko AN. Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence. Expert Opin Biol Ther 2010;10:653-666.
20. Hartung HP. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Expert Opin Pharmacother 2009;10:291-309.
21. Feinstein A, O'Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b and depression A prospective investigation. J Neurol 2002;249:815-820.
22. Lotrich FE. Major depression during interferon alpha treatment: vulnerability and prevention. Dialogues Clin Neurosci 2009; 11:417-425.
23. Sockalingam S, Abbey SE. Managing depression during hepatitis C treatment. Can J Psychiatry 2009;54:614-625.
24. Erim Y, Tagay S, Beckmann M, et al. Depression and protective factors of mental health in people with hepatitis C: a questionnaire survey. Int J Nurs Stud 2010;47:342-349.
25. Reith DM, Edmonds L. Assessing the role of drugs in suicidal ideation and suicidality. CNS Drugs 2007;21:463-472.
26. Goeb JL, Even C, Nicolas G, et al. Psychiatric side effects of interferon-beta in multiple sclerosis. Eur Psychiatry 2006;21: 186-193.